vTv Therapeutics Inc. (VTVT)
NasdaqCM
Price as at 1 Oct 2026, 03:47 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
vTv Therapeutics Inc. trades at $30.84. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$10.16M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$1.49M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$657.1K · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$432.4K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$223.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own VTVT?
6 of the institutions we track reported a position in VTVT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its VTVT data?
Fundamentals for VTVT come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 03:47 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for VTVT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.